Cell Therapy Market Report 2025

The cell therapy market size has grown rapidly in recent years. It will grow from $14.56 billion in 2024 to $17.02 billion in 2025 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to early research and discoveries, regulatory milestones, clinical trials and studies, early adopters and pioneering companies, market acceptance and perception.

The cell therapy market size is expected to see rapid growth in the next few years. It will grow to $29.28 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to ethical and societal considerations, investment and funding trends, consumer/patient demand, healthcare infrastructure, rapid innovation cycles. Major trends in the forecast period include personalized medicine, emerging targeted treatments, gene editing technologies, stem cell research expansion, immunotherapy advancements, microenvironment manipulation.

The increasing prevalence of chronic diseases has facilitated the growth of the cell therapy market. According to the US Centers for Disease Control and Prevention (CDC), chronic diseases are conditions that persist for a year or more, require medical attention, limit daily activities, or both, and include illnesses such as heart disease, cancer, diabetes, and Parkinson’s disease. Stem cells can provide benefits to patients suffering from various conditions, including spinal cord injuries, type 1 diabetes, Parkinson’s disease (PD), heart disease, cancer, and osteoarthritis. For example, in July 2024, the CDC reported significant updates regarding public health initiatives. Each year, over 944,800 Americans die from heart disease or stroke, which accounts for more than one-third of all deaths. In the U.S., 1.7 million individuals are diagnosed with cancer annually, resulting in over 600,000 deaths, making it the second leading cause of death. Additionally, more than 38 million Americans have diabetes, and another 98 million adults are prediabetic, increasing their risk of developing type 2 diabetes. Diabetes can lead to serious complications such as heart disease, kidney failure, and blindness. Furthermore, obesity affects 20% of children and 42% of adults, heightening the risk of chronic diseases like type 2 diabetes, heart disease, and certain cancers. The rising prevalence of chronic diseases has heightened the demand for cell therapies, contributing to the expansion of the cell therapy market.

Increasing investments are anticipated to drive the growth of the cell therapy market in the future. Investment in cell therapy refers to the allocation of financial resources, capital, or funding aimed at supporting the research, development, manufacturing, and commercialization of cell-based therapies. Such investments are being utilized to further research and develop new cell therapy products and technologies, as well as to conduct clinical trials evaluating these products, which will enhance and improve cell therapies. For instance, in 2023, the BioIndustry Association (BIA), a UK-based organization representing the life sciences and biotech industry, reported that UK cell and gene therapy companies secured over 55% of the venture capital funding obtained by European firms. The UK generally accounts for around one-third of all European venture capital investments in life sciences, underscoring the strength of its cell and gene therapy sector. In contrast, US companies captured 86% of the venture funding for cell and gene therapies in 2022 and are expected to outpace their international counterparts in 2023. Thus, rising investment is fueling the growth of the cell therapy market.

Key market players are strategically forming partnerships and collaborations to enhance their product portfolios and expand their geographical reach. In November 2023, Ajinomoto Co Inc., a Japan-based food company, acquired Forge Biologics for $620 million. This acquisition is intended to strengthen Ajinomoto Co Inc.’s global capabilities in AAV and plasmid gene therapy manufacturing, thereby enriching and reinforcing its existing contract development and manufacturing services. Forge Biologics is a US-based biotechnology company dedicated to advancing cell therapy technologies for various diseases.

Leading companies in the cell therapy market are pursuing strategic partnerships to deliver innovative and effective therapies to patients. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits and success. For instance, in September 2022, Genentech Inc., a US biotechnology corporation, entered into a partnership with Arsenal Biosciences, Inc., a US-based programmable cell therapy company. This collaboration aims to expedite the development of next-generation cell therapy products, potentially leading to new and more effective therapies for solid tumors - a significant breakthrough for cancer patients. Both companies are committed to investing in new technologies and delivering innovative treatments to those affected by cancer.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Sigilon Therapeutics for $34.6 million. This acquisition aims to bolster Lilly’s research and development efforts in encapsulated cell therapies, specifically focusing on Type 1 diabetes with its lead candidate, SIG-002. This strategic move will enhance Lilly's position in the diabetes treatment market. Sigilon Therapeutics is a US-based biotechnology company concentrating on the development of innovative cell therapies.

Major companies operating in the cell therapy market include Celgene Corporation, JCR Pharmaceuticals Co. Ltd., Baxter Healthcare Corporation, Nipro Corp., Stempeutics Research Pvt. Ltd., Osiris Therapeutics Inc., Vericel Corporation, AlloSource, Anterogen Co. Ltd., Arteriocyte Medical Systems Inc., MediPost Co. Ltd., Pharmicell Co. Ltd., Corestem Inc., Stemedica Cell Technologies Inc., Adaptimmune Therapeutics plc, Mesoblast Ltd., Cell Medica Ltd., Cellerant Therapeutics Inc., Kolon TissueGene Inc., Tego Science Inc., Athersys Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Forticell Bioscience Inc., Bone Therapeutics, Holostem Terapie Avanzate S.r.l, Fibrocell Science Inc., AlloCure Inc., TiGenix NV, Cells for Cells, AVROBIO Inc., Cellular Biomedicine Group Inc., Thermo Fisher Scientific Inc., Merck Co. & KGaA, Charles River Laboratories International Inc., Lonza Group Ltd., Catalent Inc.

North America was the largest region in the cell therapy market in 2024. The regions covered in the cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cell therapy involves the replacement or repair of damaged tissue and/or cells by transplanting human cells. Various types of cells can be employed as part of a therapy or treatment for a range of diseases and disorders, leveraging new technologies, innovative products, and boundless imagination. This treatment form entails the administration of live cells to patients through injection, grafting, or implantation to achieve a therapeutic outcome.

The primary techniques employed in cell therapy include stem cell therapy, cell vaccines, adoptive cell transfer (ACT), fibroblast cell therapy, and chondrocyte cell therapy. Stem cell treatment, also recognized as regenerative medicine, utilizes stem cells or their derivatives to stimulate the healing response in diseased, defective, or injured tissues. Allogeneic therapies and autologous therapies are the two main types of therapies used in various applications such as oncology, cardiovascular disease (CVD), orthopedics, wound healing, and more.

The cell therapy market research report is one of a series of new reports that provides cell therapy market statistics, including cell therapy industry global market size, regional shares, competitors with a cell therapy market share, detailed cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy industry. This cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cell therapy market includes revenues earned by entities by enhancing the growth of new healthy skin tissue and enhancing collagen production. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.